Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04), FiscalAI reports. The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Mitapivat revenue reached $44.7 million in Q2, including $40.9 million in the U.S., while AQVESME generated 442 cumulative prescriptions from REMS-certified physicians. Payer coverage for U.S. thalassemia patients reached approximately 75%.
• The FDA accepted mitapivat’s sickle cell disease supplemental application for priority review with a November 1, 2026 PDUFA date; Agios is preparing for a potential launch, though the indication is not expected to materially contribute to 2026 revenue.
• Thalassemia launch dynamics are shifting toward a broader non-transfusion-dependent population, which may lengthen treatment initiation to the expected 10–12 weeks. Management will evaluate six-month patient benefit and persistence in the second half and plans to stop reporting REMS prescription counts after Q3 in favor of revenue metrics.
• Agios expanded its rare hematology pipeline by licensing cevidoplenib, a selective oral Syk inhibitor for immune thrombocytopenia, and plans to advance AG-236 into a seamless Phase II/III polycythemia vera program in the second half of 2026.
• The company ended the quarter with approximately $1 billion in cash and marketable securities, but operating expenses increased as commercial investment expanded; full-year operating expenses are expected to remain roughly flat versus 2025 excluding the $25 million cevidoplenib upfront payment.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded down $2.26 on Thursday, reaching $32.75. 3,134,451 shares of the company’s stock traded hands, compared to its average volume of 1,054,030. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -4.52 and a beta of 0.54. The stock has a 50 day moving average price of $34.37 and a 200-day moving average price of $30.86.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AGIO. Royal Bank Of Canada boosted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Bank of America upped their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. The Goldman Sachs Group increased their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. HC Wainwright boosted their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Truist Financial lifted their target price on shares of Agios Pharmaceuticals from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $40.38.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $25,000. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $49,000. Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the third quarter valued at $79,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $133,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.